HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.
Viruses. 2021 Mar 5;13(3):413. doi: 10.3390/v13030413.
The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in , , , , , , and , among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug-drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19.
新型冠状病毒病 2019（COVID-19）的治疗一直是一个挑战。已经评估了几种药物的疗效，并观察到药物反应的可变性。药物遗传学可以解释这种差异，并改善患者对这种复杂疾病的预后；然而，在 COVID-19 治疗的药物遗传学研究中，必须仔细审查几个与疾病相关的问题。我们旨在描述用于 COVID-19 治疗的药物（瑞德西韦、奥司他韦、洛匹那韦/利托那韦、阿奇霉素、氯喹、羟氯喹、伊维菌素和地塞米松）的已报道的药物遗传学变异体。此外，还提到了与药物遗传学研究设计相关的其他因素。、、、、、、和其他变异体中的变异体可以包含在 COVID-19 治疗的药物遗传学研究中。此外，在寻找 COVID-19 的个体化治疗时，除了药物遗传学因素外，还应考虑药物相互作用和炎症等非遗传因素。
